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Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could
produce complete responses (CRs) that were often durable for decades without further therapy. The majority of
complete responders with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) could probably
be classified as “cures”. Recent publications have suggested improved efficacy, perhaps due to improved patient
selection based on a better understanding of clinical features predicting outcomes. Guidelines for clinical management
were established from experience at the National Cancer Institute (NCI) and an affiliation of institutions known as the
Cytokine Working Group (CWG), who were among the first to utilize HD IL-2 treatment outside of the NCI. As new
centers have opened, further management variations have emerged based upon center-specific experience, to
optimize administration of IL-2 and provide high quality care for patients at each individual site. Twenty years of
evolution in differing environments has led to a plethora of clinical experience and effective management approaches.
The goal of this review is to summarize the spectrum of HD IL-2 treatment approaches, describing various effective
strategies that incorporate newer adjunctive treatments for managing the side effects of IL-2 in patients with mRCC
and mM. The goal for IL-2 therapy is typically to administer the maximum number of doses of IL-2 without putting the
patient at unacceptable risk for severe, irreversible toxicity. This review is based upon a consensus meeting and includes
guidelines on pre-treatment screening, criteria for administration and withholding doses, and defines consensus criteria
for safe administration and toxicity management. The somewhat heterogeneous best practices of 2014 will be
compared and contrasted with the guidelines provided in 2001 and the package inserts from 1992 and 1998.
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Interleukin-2 (IL-2) was historically one of the few treat-
ments for adults with stage IV solid tumors that could
produce complete responses (CRs) that were often durable
for decades without further therapy. The majority of
complete responders with metastatic renal cell carcinoma
(mRCC) and metastatic melanoma (mM) could probably
be classified as “cures”. Despite this remarkable response
quality in a small minority of patients, the requirement
for hospitalization at expert immunotherapy centers to
manage the side effects of high dose IL-2 (HD IL-2)
administration has limited its utilization. Early studies
evaluated high dose IL-2 in comparison with lower
doses both in mRCC and mM in an effort to minimize* Correspondence: jpd4401@aol.com
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unless otherwise stated.toxicity. However the data demonstrated superiority of
the high dose (HD) regimens in both diseases [1-4]. Faced
with the task of administering of HD IL-2, guidelines for
clinical management were established from experience at
the National Cancer Institute (NCI) [5-7]. An affiliation
of institutions known as the Cytokine Working Group
(CWG), who were among the first to utilize HD IL-2
treatment outside of the NCI, led the implementation
of management strategies in new settings [8]. Currently
there are more than 60 centers in North America admin-
istering HD IL-2 for mRCC and mM. As new centers have
opened, further management variations have emerged,
based upon center-specific experience, to optimize admin-
istration of IL-2 and provide high quality care for patients
at each individual site. Twenty years of evolution in
differing environments has led to a plethora of clinical
experience and effective management approaches.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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perhaps due to improved patient selection based on a
better understanding of clinical features predicting out-
comes [9-11]. At the same time, the number of doses
of IL-2 being administered per course has decreased,
reducing toxicity without an apparent impact on efficacy
[1,2,7-10,12-14]. These trials have stipulated the standard
dose and schedule of HD IL-2, but this delivery and
management could vary according to each site’s toler-
ance for specific toxicities and approach to managing
them. Virtually no information exists in the literature
regarding the specifics of administration practices or
median doses per cycle given at major HD IL-2 centers.
In recent years, new therapies have been approved in
both mRCC and mM. Prior treatment with these new
agents may influence the eligibility of patients for HD
IL-2, modify their response, or change the management
strategies of HD IL-2. In many instances, little infor-
mation exists in the literature regarding the integration
of HD IL-2 therapy with other treatments and more
guidance would be desirable.
The goal of this review is to summarize the spectrum
of HD IL-2 treatment approaches, describing various
effective strategies that incorporate newer adjunctive
treatments for managing the side effects of IL-2 in
patients with mRCC and mM. The goal for IL-2 therapy is
typically to administer the maximum number of doses
of IL-2 without putting the patient at unacceptable risk
for severe, irreversible toxicity. This review is based
upon a consensus meeting and includes guidelines on
pre-treatment screening, criteria for administration and
withholding doses, and defines consensus criteria for safe
administration and toxicity management. The somewhat
heterogeneous best practices of 2014 will be compared
and contrasted with the guidelines provided in 2001 and
the package inserts from 1992 and 1998.
Early physiology investigations of high dose IL-2 therapy
In the 1980’s and 1990’s, clinical trials evaluating the effi-
cacy of HD IL-2 yielded a great deal of information on
the physiologic effects of exogenous, HD recombinant
IL-2 administration in humans [15-27]. Early clinical stud-
ies employed IL-2 often in combination with adoptively
transferred lymphocytes referred to as Lymphokine Acti-
vated Killer (LAK) cells. In these studies, it was not
possible to separate the contribution of each modality
in terms of clinical response and emergence of treatment-
related adverse events. Further complicating the picture
was the fact that the dose and schedule of IL-2 admin-
istration often varied from study to study. Although the
specific molecular and cellular mechanisms of IL-2-
mediated response and toxicity are not completely
defined, IL-2 is known to result in a cascade of cyto-
kines released at supraphysiologic levels in the body fromIL-2-activated cells. This can result in a well-described
capillary leak syndrome and eventual end-organ dys-
function [15-27]. The hallmarks of this “cytokine storm”,
are remarkably similar to the shock syndrome associated
with bacterial septicemia, and include: sustained hypo-
tension, tachycardia and increased vascular permeability.
In addition, high serum cytokine levels appear to be
directly or indirectly toxic to the cells of multiple organs
[28,29]. Early animal and human studies suggested a
dose–response effect on both efficacy and toxicity [15-17].
Thus most of the early literature described alternative
methods of managing these patients than those used for
sepsis, as the desirable therapeutic effects were thought to
be linked to the toxicity (5–8,24-27) and the inciting factor
(IL-2 administration) was within the physician’s control.
Studies of cardiovascular physiology evaluated the
universal hypotension associated with HD IL-2 admin-
istration and demonstrated high cardiac output and
reduced peripheral vascular resistance (42% mean decrease)
and a decline in mean cardiac ejection fraction from
between 58% to 52% [24-26]. Six of ten patients in one
study in which patients received HD IL-2 alone, had
reductions in their LVEF of 5% (absolute number) or
greater. In a smaller study where patients were also
administered LAK cells, mean ejection fraction fell
from 58 to 36%. An increase in ejection fraction would
be expected with the increased inotropy and decreased
afterload associated with hypotension. These studies
suggested that HD IL-2 administration and the associated
high serum levels of other cytokines, produced toxic
effects on the myocardium which are worsened by the
co-administration of LAK cells. Based upon temporal
correlation of levels, TNF-α, may be the central cyto-
kine in this response [27]. Both studies demonstrated
complete recovery of all parameters, even at 14 days,
following IL-2 administration cessation.
Renal dysfunction was virtually always reversible, and
was evaluated as being both pre-renal and renal in origin
[30-32]. The sustained hypotension certainly reduces
renal blood flow and results in a pre-renal dysfunction
characterized by high aldosterone and renin, and high
tubular recovery of sodium. Patients receiving HD IL-2
may become severely oliguric and even anuric, but rarely
manifest acute tubular necrosis, as might be expected
with purely hypotensive effects. The falling BUN:creatinine
ratio and decreased filtration fraction speaks to an intrinsic
renal defect probably mediated by a downstream cytokine.
The minimal proteinuria suggests that the increased vascu-
lar permeability seen in the rest of the body is not active
at the glomerular level. The rapid and complete recovery
suggests that no real structural damage occurs during IL-2
treatment.
Infections were a frequent cause of adverse events and
even death in early trials of HD IL-2. The majority of
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largely with gram positive bacteria. These were attributed
to the use of central venous multiport catheters necessary
to administer high rates of fluids or vasopressor medication
[33,34]. Aseptically-placed catheters developed infections
much earlier than would have been predicted. A granulo-
cyte migration defect observed in patients receiving HD
IL-2 was postulated to have permitted local infections to
become systemic [33]. The use of prophylactic antibiotics,
fresh placement and removal of intravenous catheters
with each cycle of treatment have largely addressed this
issue [6,7].
Making standard recommendations regarding the
amount of HD IL-2 administration is complicated, as
IL-2 is typically delivered as an intravenous bolus with
a fixed dose based on individual patient weight (typically
either 600,000 or 720,000 Units/kg) and then that dose
delivered every 8 hours up to a maximum of 14–15 doses
subject to toxicity. Most patients receive one course of
treatment that consists of two cycles separated by a 9–14
day holiday before re-staging. The first cycle of each
course has been associated with more doses than the
second in the vast majority of individuals. Comparing
total dosing is also confounded by the dropout of non-
responders after the first course. Studies do not report
dosing in any routine fashion making comparisons diffi-
cult. Evolution of management during the first decade
of treatment with HD IL-2 at the NCI resulted in a 58%
reduction in number of doses in the first cycle of IL-2,
with a concomitant significant reduction in grade 3 or
4 toxicity (reduction in diarrhea by 80%, reduction in
neurotoxicity by 50%, reduction in serious pulmonary
toxicity by 75%, and reduction in mortality to zero) [7].
An average of 8 x 720,000 IU/kg (equivalent to about 9
600,000 IU doses) was established for the first cycle at
the NCI. Although no statistically significant difference
in the CR rate or response duration for either mRCC or
mM patients was associated with these changes some
early studies showed correlation of response with the
number of doses [1,7,35]. Studies in the succeeding
decades by the CWG, have shown a modest decrease in
the number of doses administered during the first course,
from a mean of 22 in the 1980’s-early 1990’s, [3] to a mean
of 19 in studies published in early 2000’s, [2] to 16–20
doses in most recent studies [9,10,13]. Variations in
response rate are within the bounds expected from rela-
tively small trials, [9,10,13] and an acceptable level of
grade 4 toxicity has been achieved without sacrificing
efficacy [9,10,13]. All recent studies demonstrate rapid
reversibility of all expected IL-2 related toxicities.
Review: Where is high dose IL-2 management today?
Screening of patients has changed as medical practice and
technology has changed. Management of cardiovasculardisease is dramatically different now than 25 years ago.
Physiologic age is recognized as more important than
chronological age. Prior therapy in patients encompasses
many more options, some of which may influence eligibil-
ity for and tolerability of HD IL-2. Current approaches to
toxicity management are more variable, but largely with
the same technology. The same fluids and vasopressors
are used for the management of hypotension. Advances
in anti-nausea agents have improved this aspect of care.
The site in the hospital where IL-2 is administered (ICU
vs step down unit, vs regular inpatient ward) and the
aggressiveness in the number of doses per cycle are highly
variable from site to site. Different parameters for screen-
ing and management are utilized according the experience
and comfort of the site personnel. The tables in this paper
show recommended ranges for continuous variables and
variations in management beyond the typical approach.
Screening (Table 1)
Substantial changes in the supportive and interventional
management of disease as well as diagnostic technology
have occurred during the past 3 decades. In addition, new
therapies have become available whose chronic toxicity
may impact a patient’s ability to receive HD IL-2 subse-
quently. HD IL-2 package insert instructions are based
upon literature and experience generated during the
1980’s and 1990’s. What was viewed as an absolute contra-
indication to therapy or a screening necessity in the past
may not be sensible in today’s environment. Nonetheless,
careful attention to screening of patients prior to IL-2
treatment remains critical to successful and safe adminis-
tration of this treatment. Patients with eligibility concerns
should always be evaluated by the relevant subspecialist
prior to therapy and ideally followed by that physician
during therapy. Less experienced sites, however, should
always err on the side of more conservative screening.
The single most important parameter for screening is
a patient’s functional - or performance - status, as mea-
sured by the ECOG or Karnofsky score as this predicts
likelihood of response, as well as, tolerance of the ther-
apy. Only patients with intact (ECOG = 0 or K = 100) or
minimally impaired (ECOG = 1 or K = 80–90) function
are candidates for HD IL-2. Functionality represents an
excellent sum of the patient’s total organ and physical
reserve which will be severely taxed during therapy.
Secondly, the histologic and molecular subtypes of RCC
and melanoma have led to more stringent selection by
histology (see variations on disease type in Table 1) based
on likelihood of response to IL-2 therapy [36].
Cardiovascular
Although cardiac toxicity remains a major concern in
HD IL2 treatment, the baseline risk has diminished in
the general population in recent decades. The reduction
Table 1 Pre screening recommendations for high dose IL-2 therapy
Package insert guidelines Current best practices
Disease MM or
mRCC
MM: cutaneous better than mucosal/ocular mRCC:
clear cell/mixed histology
PS 0-1 0-1
Cardiac function All patients Under 40–50 without history
Thallium stress test-normal Selective testing only
Over 40–50 or prior history
EKG stress test-normal (off beta blockers)
CAD corrected > 6–12 months
EKG stress test, EF, motility-normal
Cardiology consult
Prior TKI
3 month gap if possible
EKG stress test, EF, motility-normal
Abnormal stress test
Cardiology consultation
Pulmonary function All patients Under 40–50 without history
PFTs with ABGs Selective testing only
Over 40–50 or with history of smoking or pulmonary disease
FEV1≥ 75% predicted
Brain metastasis No untreated CNS metastasis Negative MRI
Positive MRI
Treated, asymptomatic, off steroids
Infection No active infections No active infections
Renal function All patients Serum creatinine ≤ 1.5 mg/dL
Serum creatinine≤ 1.5 mg/dL Serum creatinine 1.5-2.0 mg/dL
Creatinine clearance > 60 ml/min
Laboratory All patients Bilirubin≤ 2.0 mg/dL
Values within normal limits Platelet count > 100,000
Hemoglobin ≥ 9.0 g/100 ml
ANC ≥ 1500/mm3
SGOT < 3x ULN
Thyroid function normal
Other No steroids, autoimmune disease, allografts
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drugs and management of hypertension and cardiovas-
cular disease has significantly reduced the incidence of
occult cardiac disease. The use of coronary artery bypass
grafts and stents has corrected existing CAD with pres-
ervation of cardiac functional reserve. Careful attention
to family history, risk factors and lifestyle is important in
determining the extent of cardiac risk and degree of
screening needed in preparation for HDIL2 treatment.
Although the package insert mandates thallium screen-
ing in all patients, most sites follow different approaches,
as the thallium stress test produces many false positiveresults. Patients below the age of 40–50 without relevant
history or risk factors generally may not require exten-
sive screening. Additionally, patients with prior history
of coronary artery disease which has been corrected may
be considered for treatment if this occurred at least
6–12 months in the past, but should be tested [37,38].
The extensive use of VEGF targeted tyrosine kinase
inhibitors in mRCC is an important historical issue. These
agents can be cardiotoxic and can produce reductions in
left ventricle ejection fraction, particularly if treatment
duration has exceeded one year. Ideally, patients should
be off anti-vascular endothelial growth factor receptor
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before HD IL-2 [39]. Careful and complete screening is
mandatory in these patients. An EKG exercise treadmill
stress testing is the standard modality for testing patients.
Ultrasound assessment of ejection fraction and myocardial
wall activity are valuable parts of the stress test and may
be employed in patients with risk factors. Ideally, stress
testing should be done with the patient off of beta
blockers, as they will be discontinued during HD IL-2
therapy. Dipyridamole (Persantin®) stress testing may be
used in patients unable to effectively use a treadmill. If the
stress test is abnormal, a cardiologist should be consulted,
and ultimately determine both the need for and the path
of further evaluation to help make a final decision about
eligibility.Pulmonary
Due to pulmonary fluid overload and the demand on the
myocardium caused by hypotension, adequate oxygen-
ation of the blood may be an issue. Smoking history and
careful attention to diseases compromising pulmonary
function are important signs of reduced pulmonary reserve.
Restrictive lung disease may be debilitating during the
stress of therapy. Patients without relevant history below
the age of 40–50 do not require screening unless there are
risk factors or signs or symptoms of underlying pulmonary
dysfunction. An FEV1 > 75% of predicted is adequate
for predicting IL-2 tolerability. Any other tests should
be ordered at the discretion of a pulmonary consultant.
Pulmonary function studies may also be useful for defining
the patient’s baseline pulmonary function, which can help
in management of changes observed during treatment.Brain metastasis
Good quality magnetic resonance imaging of the brain
should be obtained prior to starting HD IL-2. Patients
with brain metastases were often considered not to be
candidates, however, with the advent of stereotactic
radiotherapy, an asymptomatic patient with adequately
treated isolated brain metastases and off systemic corti-
costeroids can be considered for treatment. Similarly,
patients with small untreated brain metastases that are
limited in number and causing minimal or no edema
may be considered for IL-2 treatment [40].Effusions
Patients with large pleural effusions or large amounts of
abdominal ascites are not good candidates for HD IL-2.
The fluid shifts experienced during IL-2 treatment gen-
erally results in expansion of existing fluid collections
and will likely result in exacerbation of symptoms that
will preclude effective therapy with IL-2.Infections
All patients should be carefully screened for infection
prior to IL-2 treatment and any active infection should
be fully treated and the patient should be off antibiotics
prior to starting a cycle of HD IL-2. This includes clear-
ance of C. difficile if that has been identified. In addition,
tumor related impingement on structures which might
lead to closed space or obstructive infections should be
carefully evaluated and corrected if necessary.
Other
Most other parameters are assessed according to labora-
tory values which are listed in Table 1.
In the hands of experienced therapy teams, treatment
can be customized with a sense of the patient’s physiologic
reserve. This will help to guide the setting of the target
blood pressure, the need for specialist support and the
threshold for stopping and holding doses of IL-2.
Site of administration unit
HD IL-2 administration requires trained experienced staff
and an inpatient location where cardiac and O2 saturation
monitoring are available and vasopressor agents such as
dopamine and phenylephrine can be administered accord-
ing to hospital policy. In addition, a low nurse to patient
ratio is necessary. These requirements are fulfilled in spe-
cialized oncology floors, transplantation units, intensive
care step down units or intensive care units in various
institutions. Novice sites might be advised to treat up
to 10 patients in an intensive care setting until they are
comfortable, then move to a less intensive and expensive
setting, provided there is sufficient clinical support. If
intensive care nurses or physicians are involved, they
should be carefully trained in how to care for the HD IL2
patients, as management is often counterintuitive to the
management of the usual intensive care patient. Transfer
of patients from one setting to another is to be avoided if
at all possible as nursing continuity is critical [41]. If
patients being managed outside the ICU develop problems
that cannot be managed safely in the current location (e.g.
cardiac arrhythmia, respiratory failure, bacterial sepsis)
such patients should be promptly transported to an ICU
and further IL-2 treatment stopped.
Overall schedule and dose
Most centers continue to utilize the original empirically
defined NCI schedule of one week on (cycle 1), one
week off, one week on (cycle 2), defined as one “course”
of treatment. The inter-cycle time may be extended by
another week based upon patient recovery or site prefer-
ence. The disease response, assessed at 6–12 weeks from
therapy initiation, after a full course of therapy helps
determine the value of administering another course.
Any response is generally viewed as a reason to give
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additional 4–6 weeks or longer followed by reassessment
may inform the decision for further dosing. Continued
disease stability over months in a patient with clearly
progressive disease before therapy is frequently, although
not always, viewed as reason to continue treating. Of note,
in one study, 90% of patients that achieved a response to
treatment, did so after one course of IL-2 [42]. In light of
these observations, decisions about additional courses
of IL-2 should be individualized based on toxicity of
prior therapy, extent of residual disease and availability
of alternative treatment options. The interval between
courses may vary considerably for a variety of other
reasons including patient recovery and logistics. The
standard dose of HD IL-2 remains 600,000 IU/kg (based
on initial studies), although higher and lower approaches
have been described in the literature [1-13,43]. The NCI
and some sites use 720,000 IU/kg [1]. For the most part,
doses are given as a short bolus infusion (over 15 minutes)
every 8 hours, over the course of 5 days. Toxicities gener-
ally occur over the 6 hours following a bolus dose, abating
before the next scheduled dose. If recovery from the previ-
ous dose is not noted at 8 hours, some centers skip a dose
and resume the 8 hour schedule. Some sites extend the
time between doses to 12 hour intervals at this juncture.
Individual dose reductions should not be used. Treatment
extends for 5 days, stopping when the 14th planned dose
would have been administered (end of day 5) regardless of
the number of doses administered. Treatment is typically
concluded earlier when adverse events occur that make
further dosing intolerable, thus only a small minority of
patients receive all 14 doses. The IL-2 treating physician
will decide when to hold or stop dosing during a cycle
based upon criteria to be discussed later in this paper. The
current total mean number of doses administered is in the
range of 16–20 of the 28 maximum doses in the two
cycles of treatment.
Some institutions have adopted schedules that continue
to use the standard amount of IL-2 per dose but offer varia-
tions in dosing interval and number of dosing cycles
[12,44]. These approaches indicate that interest remains in
optimizing IL-2 therapy in ways which maintain efficacy
but improve the safety profile for patients. Little data exists
on the dose response curve, however, the response rate
between 600,000 or 720,000 IU/kg (HD) and 72,000 IU/kg
(moderate dose) is significantly different [1].
Initial admission and management – standing orders
(Additional file 1)
Most centers have a set of routine IL-2 orders that es-
tablish the basic procedural approach of the local IL-2
team. Although these vary considerably from site to site,
they are strictly adhered to within a site, in order to
maintain continuity among nursing shifts and facilitateclinical decision making. Standard protocols for main-
taining intravenous access catheters, intravenous fluids,
prophylactic-and as needed (PRN) medications for symp-
tom control, monitoring parameters, and daily laboratory
evaluations, guide the daily management of patients.
Reactive management of expected complications, such as
hypotension, decline in oxygen saturation, tachycardia, and
alterations mental status should also be listed. Threshold
values for various monitoring parameters should be listed
which require contacting the physician. Standing order
specifics are imbedded in Table 2. Additional file 1 provides
an example of standing orders. These parameters take into
consideration the standards in each clinical unit, the type of
monitoring available and the philosophical approach of the
team. The frequency of blood testing is usually once daily,
with additional testing as needed and directed by the IL-2
physician. Patients are admitted to the hospital the evening
before or the morning of the first IL-2 infusion. The most
common dosing schedule is 8 AM, 4 PM and midnight
often with the first dose being administered at 4 PM on
day 1.
Toxicity management by organ system – typical
management and variations (Table 2)
The most important skill in managing an HD IL-2 patient
is to understand when to withhold the next dose. Acute
inter-dose exacerbations peak around 4–6 hours following
each dose. Before another dose is given, patients should
be approaching or have returned to their target baselines
for heart rate, oxygen saturation and blood pressure. There
should be capacity to provide increased blood pressure and
oxygenation support during the inter-dose exacerbation
which will follow administration of the next dose. Toxic-
ities are generally cumulative, worsening and becoming
refractory to management with successive doses during the
week. Preparing patients and family to expect symptoms
will alleviate their fears and enlist their support.
Fever/chills
These are the first side effects encountered by patients and
can be quite disconcerting. Almost all patients have fever
with at least the first IL-2 dose, despite premedication, usu-
ally within 30–60 minutes after the dose. Over the week,
these symptoms generally lessen with subsequent doses.
Both acetaminophen and non-steroidal anti-inflammatory
agents (NSAIDS) are administered prophylactically and as
needed for fever. Continuous NSAIDS are not a problem
despite a rising creatinine, in view of the universal revers-
ibility of the renal adverse events seen with IL-2. However,
holding or withdrawing NSAIDS later in the course when
the creatinine rises above 3–4 mg/dL is prudent.
Often fever comes after an episode of severe chills or
rigors. Significant rigors are effectively managed by giving
parenteral opioids immediately at the onset of the rigor.
Table 2 Clinical management recommendations for HD IL-2 therapy
Issue Considerations Management
Venous access Central line (for possible vasopressors) Typical
Double or triple lumen PICC line placement
Power inject and large volume capacity Remove temporary lines at end of cycle
Minimize catheter associated infection Variations
Broviac/Hickman catheter
Subclavian/IJ catheter
IV fluids Maintenance of volume with CLS Typical
Boluses for blood pressure support D5NS or D5LR 10 ml – 125 ml/hr
Administration of drugs PRN KCL, HCO3, Mg replacement
Replacement of electrolytes Variations
IL-2 only compatible with D5W D5W, NS, 0.45% NaCl
Infections No active infections Typical
Prevention Gram + prophylactic antibiotic
IV catheter likeliest source Variations
Avoid unnecessary in-dwelling catheters Expanded coverage per hospital
Chills/rigors Chills and rigors occur 1–2 hrs after IL-2 Fever-Typical
Prophylaxis
Fever Fever is common 2–4 hrs after IL-2 Acetaminophen 650 mg 30 min pre-dose,
q 4–6 hrs and prn
Indomethacin 25 mg q 6–8 hrs
Constitutional
symptoms
Muscle joint aches continuous and progressive
during IL-2 treatment
Fever-Variation
Naproxen
Ibuprofen
Chills-Typical
Meperidine 25 mg IV q 15 m prn
Morphine 2–4 mg IV q 15 m prn
Nausea/vomiting Episodic occurrence throughout therapy Typical- Prophylaxis
Nausea > vomiting Ondansetron 0.15 mg/kg q 8 hrs
Variations
Granisetron 1 mg daily
Ondansetron at longer interval
Compazine 10 mg po q 6 hrs
Use of antinausea agents prn
Epigastric distress Gastritis induced by stress, medications Typical
H2 blocker prophylaxis
Variation
PPI prophylaxis
Mucositis/stomatitis Progressive with continued treatment Typical
No prophylaxis
Oncology mouthwash
Diarrhea Can be profuse and increases with therapy Typical
5HT-3 antagonist anti-emetic prophylaxis Imodium
may have positively impacted Lomotil
Narcotic
Break between IL-2 doses
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Table 2 Clinical management recommendations for HD IL-2 therapy (Continued)
Variations
5HT-3 antagonist prophylaxis
Patient monitoring I & O, Weight Per shift and daily
Blood pressure, pulse, respirations, temp Q 2-4 hrs
Blood work Daily
EKG Continuous cardiac monitoring
O2 Saturation Q 2–4 hrs
Mental status examination Q 8 hrs
Increase frequency as needed
Aldesleukin/Interleukin-2
dose and administration
IL-2 incompatible with salt solutions. Typical: 600,000 IU/kg infused over 15 minutes
Q 8 hrs up to 14 doses.
Dissolve in sterile water for injection Dilute
into 50 cc D5W
Variations: 720,000 IU/kg Q 8 hrs Q 12 hrs < 14
maximum doses
Stop infusion, flush IV tubing with 50 cc D5W
before and after each dose.
Hypotension Maintain systolic BP 80–90 mm hg Fluid boluses, 250–500 ml NS
Blood pressure nadirs 4–6 hrs after each dose
with diminished recovery with cumulative dosing
2xday
Increase maintenance fluid rate
Phenylephrine 0.1-4.0 mcg/kg/min
Hold next dose
Prior to each dose anticipate ability to respond
to next nadir
DC IL-2
Variations:
Dopamine 1-6 ug/kg/min
Progressive refractoriness to support measures Pressors with minimal fluids
Fluids without pressors
Cardiac arrhythmias Sinus tachycardia Manage BP and fever
Common and progresses over a cycle
Peaks 2–4 hrs after dose with fever and hypotension
Must resolve prior to next dose
Supraventricular tachycardia, atrial fibrillation Medical Conversion
Less common Cardizem as needed
Atrial fibrillation Digoxin
Ventricular tachycardia Medical Conversion
Acute treatment
Discontinue IL-2
Renal function Typical
Oliguria Output less than 50–100 cc/8 hrs Fluid bolus,
if no improvement next shift hold IL-2 dose
Rising creatinine Creatinine >3-4
Stop NSAIDS and nephrotoxic antiobiotics
Urine output and creatinine resolve after
discontinuation of IL-2
Hold overnight dose
If am creatinine improved continue
If only one kidney always consider obstruction
of ureter
Variations
Dopamine 1–6 mcg/kg/min
Furosemide
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Table 2 Clinical management recommendations for HD IL-2 therapy (Continued)
Pulmonary Tachypnea/Dyspnea Typical
Diagnose etiology and treat Oxygen 2–4 L nasal cannula, increasing up
to 35% rebreather
Hypoxic causes-Fluid overload,
capillary leak, bronchospasm
Reassurance or sedative for anxiety, treat bronchospasm
or acidosis if appropriate
Non hypoxic causes Hold IL-2 dose if O2sat < 95%
Anxiety, fever, acidosis
Maintain O2sat > 92-5% Variation
Furosemide
Bronchodilators
Monitor bicarbonate
Peripheral edema Expect to gain 5-10% body weight Elevation, compression, limit fluid support in subsequent
cycles
Treat edema symptomatically Diuretics upon conclusion of IL-2 dosing
are not necessary but may speed process
Entrapment of peripheral nerves in upper
extremity may need therapy
Treat peripheral nerve pain
Neurotoxicity Typical
Protean manifestations Formal neuro checks
Gradual onset with sudden worsening near end of
cycle
Enlist family evaluation
May persist after cessation of therapy Lorazepam and Haloperidol
Delusions, Visual hallucinations Hold IL-2 liberally for suspected neurotoxicity
Warn patient of vivid dreams after discharge
Dermatologic Typical
Rash, erythema, dry desquamation Emollient lotions and creams Oatmeal bath
Pruritus Antihistamines
Moist dermatitis Hold IL-2 dose
Variations
Crisco
Gabapentin
Naloxone
Narcotics
Nonalcohol, no steroid topicals
Metabolic Hypomagnesemia, hypocalcemia (but low
albumin – so corrected may be WNL), Hypokalemia-
Daily electrolyte panels
Acidosis due to diarrhea, hypoperfusion Correct electrolytes cautiously prn
Hypothyroidism a slow onset problem Magnesium and HCO3, particularly if diarrhea
a problem
HCO3 < 18 meq/L hold dose of IL-2
Check TSH at beginning of cycle
RL as support fluids may decrease need for HCO3
Hepatic ↑Bilirubin (up to 10) Monitor daily
↓Albumin (down to 1.8) No intervention except if SGOT SGPT are >5x
↑Hepatic aminotransferases Resolves spontaneously
Stop acetaminophen if bilirubin > 5
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Table 2 Clinical management recommendations for HD IL-2 therapy (Continued)
Hematologic ↓Platelets Transfuse platelets if < 20 K
Lymphs ↓during IL-2, ↑post therapy Other abnormalities require no intervention
Eosinophils progressively ↑with several cycles Significant anemia needs evaluation for cause
Endocrine Hypothyroidism – slow onset after completion
of treatment
Check TFTs at beginning of cycle and monitor
TFTs with subsequent visits
Requires serial monitoring
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morphine is also used and may be less emetogenic. Fevers
and chills which occur outside the 2–6 hour window after
a dose of IL-2 must be considered as potentially due to
infection and evaluated accordingly.
Hypotension
This is the most common and important toxicity of HD
IL-2 treatment (70% of patients in early studies), reflecting
capillary leak, decreased peripheral vascular resistance
with high cardiac output, characteristic of systemic in-
flammatory response syndrome (SIRS). A variety of
causes of gap junctional instability in endothelial cells
have been postulated as the underlying mechanism for
the leak. The relationship of capillary leak to the hypo-
tension is uncertain as changes in peripheral vascular
resistance may produce decreases in blood pressure
even in the absence of capillary leak. Hypotension is
largely unavoidable and may be viewed as a clinic-dynamic
parameter for drug administration. Standing orders should
specify a new baseline tolerable systolic blood pressure of at
least 20 points lower than baseline was prior to initiating
IL-2. In addition, a wide pulse pressure should be expected
from a decrease in diastolic pressure. The baseline values
should be customized for each patient taking into account
the individual’s cardiac status and prior exposure to tyro-
sine kinase inhibitors directed at the vascular endothelial
growth factor pathway. During treatment this level of
hypotension becomes the new baseline that is the goal
for the entire dosing period. Typically, the acceptable
target systolic pressure is about 80–90 mmHg for patients
without cardiac risk factors, but may be adjusted up-
ward in patients who are at higher risk of coronary or
cerebral artery disease. Management of blood pressure
also requires maintaining an acceptable heart rate which
will be discussed later.
The management of hypotension also appears to have
the broadest spectrum of practice among centers. The
approaches hinge on a preference for using fluids versus
vasopressors to maintain blood pressure (BP). Some
centers rely solely on large volumes of saline, lactated
ringers or hetastarch to maintain blood pressure with the
expectation that the patient will gain at least a kilogram
or more per day, with a total weight gain of 5-10% of
their body weight during the week of administration.The relative values of colloids vs. crystalloids have been
studied extensively in intensive care situations with no
obvious advantages, except for cost [45]. Fluids are admin-
istered as continuous infusion or as boluses, in response
to hypotensive episodes. Initial maintenance rates vary
between of 5–125 ml/hour. Bolus sizes vary from 100 mL
to 500 mL. Since patients can experience flash pulmonary
edema, fluids should be administered cautiously during
active IL-2 treatment. Other centers will start a vasopres-
sor, particularly dopamine or phenylephrine, immediately
and more sparingly employ maintenance and bolus fluids
[46]. Patients with a history of hypertension admitted
for HD IL-2 therapy should have outpatient antihyper-
tensive medications discontinued immediately prior to
IL-2 therapy.
Examples
Center A routinely administers HD IL-2 on the oncology
unit. They utilize maintenance fluids of 75–100 ml/hour.
For hypotension, patients are initially given 250–500 mL
of saline, LR or hetastarch with a second bolus of 250 mL
allowed to raise the BP to the target systolic pressure.
Dopamine is used on the oncology unit if dose-limiting
renal dysfunction is experienced, but no other vasopres-
sors, and it is used at renal doses (1-5 ug/kg/min). If a
patient develops significant tachycardia while on dopa-
mine (greater than 120- 130/min sustained), they hold
IL-2, correct intravascular hypovolemia and allow the
patient to recover. If the patient becomes fluid over-
loaded with respiratory symptoms, they hold or stop
IL-2, and use diuretics as necessary, prior to respiratory
compromise. The goal is to administer up to14 doses/
cycle if dosing criteria are met before each dose.
Figure 1 shows a patient with a target systolic BP of 90
experiencing BP reductions with tachycardia 3–4 hours
after doses 5 and 6 of IL-2. These episodes responded
promptly to a 500 mL bolus of saline.
Center B treats patients in the ICU in order to main-
tain a lower nurse to patient ratio and permit the use of
vasopressors. Patients are given maintenance fluids of
10 ml/hour unless they have excessive nausea/vomiting
or diarrhea, in which case it is raised to 30–50 ml/hour.
Volume boluses are used as previously described for
episodes of hypotension. If this does not reverse the
hypotension, then patients are started on phenylephrine
50
100
150
0
50
100
Systolic BP
Diastolic BP
Heart Rate
Aldesleukin 4 Aldesleukin 5
Fluid
Bolus
Fluid
Bolus
2pm 6pm 2am 6am10pm
- - -Target  BP
m
m
/H
g B
P
M
Figure 1 Timing of the administration of the 4th and 5th IV boluses of IL-2 is plotted versus systolic and diastolic blood pressure and
heart rate. This patient shows characteristic exacerbation of hypertension 3–4 hours after infusion responsive to fluid boluses.
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as necessary to maintain BP, with a preset maximum
dose level individualized per patient cardiac risk factors
between doses. The phenylephrine must be tapered back
to baseline of 50 micrograms/minute or less before
another IL-2 dose is given. With subsequent IL-2 doses,
up to 2 fluid boluses per 8 hours may be administered
for hypotension if there are no signs of pulmonary
compromise or excessive (>5% baseline weight) fluid
overload, but vasopressors are the mainstay of managing
hypotension in this setting. The need for a 3rd bolus in
24 hours generally requires holding the next dose of IL-2.
Some patients become refractory to phenylephrine and
require dopamine or norepinephrine (Levophed™). Even
with this regimen, patients usually gain 10–20 pounds of
water weight during a 5 day course of treatment.
Figure 2 shows the course of a patient responding
minimally to a bolus of saline after suffering hypotension
and tachycardia after dose 6 of IL-2. Phenylephrine is
started at 50 mcg/kg/min with return of BP and HR to
acceptable levels. After the next dose hypotension and50
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Figure 2 Timing of the administration of the 6th and 7th IV boluses o
and heart rate. This patient is unresponsive to a fluid bolus and phenylep
administration of the 7th dose. The resulting hypotension and tachycardia
bolus of fluid. The late night dose will likely be held.tachycardia recur and respond minimally to an increase
in phenylephrine dose and better to an additional bolus
of saline.
Experienced centers use phenylephrine and dopamine
on an oncology or stem cell transplant unit, which has
the nursing staff trained to support such use and also have
cardiac monitoring capability. Their management practice
is similar to that described in Center B. In any scenario,
the blood pressure/heart rate must recover to a predefined
baseline prior to administering the next dose of IL2.
Cardiac arrhythmias
There is fairly uniform practice with respect to managing
cardiac arrhythmias with serious arrhythmias being uncom-
mon. Sinus tachycardia is to be expected and a new base-
line acceptable heart rate of less than 100 beats per minute
is generally recorded in the standing orders along with a
directive against the use of beta blockers. The rate typically
increases after each IL-2 dose, peaks at 2–4 hours and
returns to baseline prior to the next dose. It is a compensa-
tory response to hypotension, but is also a consequence of0
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hrine is begun at 50 mcg per minute with good effects permitting
are treated with an increase in the phenylephrine dose and another
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and fever. It is important to distinguish the cause in order
to avoid unnecessary fluid boluses. The tachycardia seems
to become more pronounced and prolonged with an
increased number of doses. It usually resolves over time
between doses and is back to baseline before the next dose.
Some centers extend the time between doses to allow
recovery and others hold a dose until the next scheduled
administration time.
Isolated premature ventricular contractions (PVCs) are
not a contraindication to continued IL-2 dosing, but if
the frequency increases (above 10/min), or patterns such
as quadrigeminy or couplets or greater arise, holding
IL-2 doses until recovery may be necessary. Less common
cardiac arrhythmias requiring immediate intervention in-
clude supraventricular tachycardia with rapid response,
atrial fibrillation with rapid response, and ventricular
tachycardia. Patients may continue IL-2, if SVT or atrial
fibrillation are converted/controlled, sinus rhythm is main-
tained or heart rate is controlled and there are no signs of
cardiac damage. Ventricular tachycardia requires evaluation
for cardiac damage and is an absolute contraindication to
more IL-2. Rarely, evidence of myocarditis or pericarditis is
noted clinically or on an EKG. This may reflect lymphocytic
infiltration [25,26]. If concerns exist regarding myocarditis
or ischemia, then cardiac enzymes or troponin should be
monitored at least daily and IL-2 discontinued if confirmed.
Dyspnea/Hypoxia
Management of dyspnea requires astute assessment and
medical judgment as to causality. HD IL-2-related respira-
tory symptoms may develop in relation to local capillary
leak or lymphocyte adherence to pulmonary vasculature or
generalized fluid overload. However, patients with a smok-
ing history, chronic obstructive lung disease or a history of
asthma may have pulmonary symptoms related to broncho-
spasm, even without significant fluid overload. All of the
preceding problems will be associated with decreased
oxygen saturation. The treatment will vary according to the
specifics. In addition, these patients may be febrile, uncom-
fortable and anxious and may be tachypneic on that basis
without associated hypoxia. Finally, an important metabolic
cause of non-hypoxic tachypnea is acidosis.
The frequency of these problems varies, and is related
to the center’s plan for management of hypotension -
aggressive fluid resuscitation versus less fluid and early
use of vasopressors. Diuretics are used by some sites,
but not recommended by most. The adverse effects on
blood pressure and kidney refractoriness within 4 hours
of a recent IL-2 dose, make this a relatively futile and
counterproductive measure. Hypoxia should be quickly
treated with nasal cannula oxygen, with increased sup-
port as necessary to maintain oxygen saturation at 95%.
In the context of hypotension with an increased demandon the myocardium, adequate oxygenation is critical and
patients should not be maintained with suboptimal sat-
uration waiting for recovery. Patients with obstructive
pulmonary disease may benefit from regular nebulizer
treatments with bronchodilators, and often they are able
to continue IL-2. Elevation of the patient’s bed is helpful.
Performance of a chest radiograph should be reserved
for patients with clinical indications for investigation.
Oliguria/Rising creatinine
Renal toxicity is believed to be related to a hypotension-
induced pre-renal component as well as an intrinsic renal
component mediated by secondary cytokines [29-31]. Most
HD IL-2 physicians agree that renal toxicity is a universally
reversible acute toxicity without chronic effects. It is
manifest by oliguria and rising blood urea nitrogen and
serum creatinine (Figure 3). All centers agree that renal
toxicity reverses very quickly, even after withholding one
dose of IL-2. All centers monitor renal function and urine
output, but use quite different criteria for holding doses
and different thresholds for concern. Criteria vary from
minimum concern for a rising creatinine and a threshold
of <100 mL/day urine output to creatinine thresholds
of 2.5 and 10–15 mL of urine per hour, managed on a
per shift schedule by fluid boluses. The typical range of
serum creatinine considered for concern is from 3.0 to
5.0 mg/dL. Evaluation of the rate of rise may shed further
light on the need for intervention.
There is enhanced concern for mRCC patients, due to
the presence of only one kidney in many patients, and
very rare cases from years ago in which patients suffered
permanent renal damage. In patients with anuria and only
one kidney, ureteral obstruction should be considered
and ruled out. Dialysis is not indicated during treatment
with HD IL-2. Discontinuing NSAIDS or nephrotoxic
antibiotics when the creatinine is above 3.0 mg/dL is
also prudent. The use of nephrotoxic contrast agents
for imaging studies in patients receiving HD IL-2 should
be not be prescribed as severe kidney damage may ensue.
Examples
Center A – whose approach is to maintain blood pressure
using relatively high volumes of fluid, both as maintenance
and as boluses for hypotension, will hold doses of IL-2 for
oliguria of less than 80–160 mL/8 hour, and give furosem-
ide. Most centers do not utilize diuretics except on an as
needed basis, since furosemide is only likely to be effective
if given more than 4 hours after an IL-2 dose. If there is
no diuresis, then IL-2 doses will be delayed.
Center B – who uses vasopressors and smaller volumes
of fluids, will monitor 24 hour urine output and requires
at least 100 mL/shift. If there is no improved output with
holding a dose of IL-2 or if there is steeply rising creatin-
ine, then another IL-2 dose will be held until the output
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Figure 3 Shows a week of HD IL-2 administration with typical evolution of daily serum BUN, creatinine, potassium and bicarbonate
values. In this patient the 1st and 2nd doses on day 3 are held. Spontaneous improvement occurs with conclusion of dosing on day 5.
Dutcher et al. Journal for ImmunoTherapy of Cancer 2014, 2:26 Page 13 of 23
http://www.immunotherapyofcancer.org/content/2/1/26is increased. Fluids will be given with vasopressors to
attempt to improve output.
Center C – who uses a combination of fluids and vaso-
pressors, also starts renal doses of dopamine from the
beginning of treatment. However, a prospective randomized
trial compared prophylactic use of low dose dopamine
versus initiation of dopamine in response to oliguria, and
found no benefit to prophylactic use [47]. Therefore, the
efficacy of prophylactic renal dose dopamine is not con-
firmed. Dopamine may induce tachycardia which may
prompt the holding of the next dose of IL-2.
Metabolic acidosis
Hypocarbia occurs for a multitude of reasons during
HD IL-2 treatment: pulmonary injury, renal dysfunction,
diarrhea, hypotension with high vasopressor levels resulting
in poor tissue perfusion or dilution, due to the administra-
tion of non-bicarbonate containing fluids. Bicarbonate
supplementation of IV fluids is recommended for serum
bicarbonate levels of 19 mmol/L or an absolute drop
of 4 mmol/L from baseline. If the serum bicarbonate
remains < 18 mmol/L despite replacement, IL-2 should be
held or stopped and bolus bicarbonate infusions adminis-
tered. Low sodium bicarbonate has been associated with
refractoriness to vasopressors which further decreases tis-
sue perfusion, thus worsening the acidosis. It is important
to replace the bicarbonate preemptively in order to avoid
this circumstance. Some centers use lactated ringers solu-
tion for maintenance fluids and note their patients do not
experience low serum bicarbonate levels. Most others
utilize saline for fluid support and give replacement boluses
of bicarbonate as needed. Whatever strategy is chosen it is
critical not to fall behind in patients at greater risk.
Nausea/vomiting
Nausea/vomiting does not occur with all patients, but most
centers prescribe scheduled prophylactic anti-emetics aswell as “as needed” orders. However, some patients require
intensive anti-nausea medication. The drugs preferred are
ondansetron and granisetron, but some centers use pro-
chlorperazine as initial treatment, only advancing to 5-HT3
antagonists as necessary. Patients who become symptom-
atic may benefit from conversion of oral medications to the
intravenous route.
Mucositis
Mucositis does occur, but is not a problem for every
patient. Therefore, it is managed on an as needed basis,
with local medications such as non-alcohol containing
mouthwash and toothpastes. Symptomatic mucositis may
worsen upon discharge and may require additional man-
agement advice.
Diarrhea
Diarrhea can be minimal or extensive and varies from
patient to patient. It is due to a combination of effects
such as oral antibiotics, bowel edema from capillary leak
syndrome, and other cytokine effects. It may be less of a
problem than originally described perhaps due to con-
tinuous administration of 5HT antagonists. Diarrhea can
complicate IL-2 administration due to fluid loss, electrolyte
loss, local discomfort, inflammation, and even infection.
Some centers postpone the night dose of IL-2 until the next
morning, when diarrhea is severe to allow recovery until
the next morning. Some centers convert oral antibiotics to
IV, or switch to a single daily dose of vancomycin to reduce
the possibility or impact of diarrhea.
Peripheral edema and weight gain
Edema is a consequence of the capillary leak syndrome
and fluid infusion, and in general causes discomfort but
is not serious. Administration of fluids should result in a
minimum 1–2 lb per day weight gain. Falling behind in
fluid replacement may result in administering more fluid
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and high doses of vasopressors ultimately leading to
early cessation of IL-2 dosing. (Figure 4) Careful attention
to daily weights and the rate of increase is important.
After stopping IL-2, many centers choose to initiate diur-
esis prior to discharge, and may target achieving a weight
that is within 5 pounds of admission. In general, diuretics
are not effective until about 6–8 hours after the last dose
of IL-2 and the cyclical effects of that dose begin to wane.
If peripheral edema is present when the patient is otherwise
ready for discharge, several centers send patients home with
a prescription for diuretics, but others do not, advising the
patient that diuresis will occur on its own. Mostly, this is a
comfort issue, and patients who are very uncomfortable
should receive a prescription for diuretics, usually 20 to
40 mg of furosemide depending on renal function, upon
discharge with instructions to take until edema is gone or
weight returns to the immediate pre-admission level.
Central nervous system neurotoxicity
All centers agree that this is a serious toxicity and one of
the most difficult to anticipate. In particular, it is a tox-
icity that can worsen in the absence of additional IL-2
treatment, so it is important to identify early and with-
hold IL-2 therapy until its course can be established.
Mild neurotoxicity, such as restlessness or insomnia, once
treated with benzodiazepines, should not cause interruption
of treatment with HD IL-2. Insomnia may be due to
hospitalization and immobility or from IL-2, and appropri-
ate medication should be considered. Severe neurotoxicity
is a criterion for stopping IL-2 permanently. The progres-
sive development of personality changes, hostility, confu-
sion, disorientation, hallucinations, are criteria for stopping
that cycle of IL-2 and may require intervention with anti-
psychotic medications. Although generally occurring later
in a cycle, gradual decay does not always occur, and an1 2 3 4
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Figure 4 Plots weight (actual and ideal curve), fluid support (IV rate and
gain falls behind ideal and increasing fluid and bolus support is necessary. Finadditional dose may cause a change from agitation to
psychosis. Patients need to remain in the hospital until full
recovery. Patients can be discharged on benzodiazepines
for several days if their toxicity is limited to irritability.
The most important management of CNS toxicity is con-
tinued reassurance and occasionally benzodiazepines or
haloperidol can be considered.
Peripheral neuropathy
Peripheral neuropathy is uncommon but can be quite
debilitating particularly in the upper extremities and
may limit IL-2 dosing. This is due to an entrapment/
compression syndrome in the wrist or forearm, associated
with edema [48]. Pain medications (usually codeine or
oxycodone) or medications more specific for neuropathy
(gabapentin) may be helpful.
Cutaneous toxicity
Macular rash, redness and dry skin are common during
IL-2 treatment, and progress as the week of treatment
continues. All centers provide topical medications dur-
ing treatment such as emollients, non-alcohol containing
lotions, or non-steroid containing lotions or creams. Skin
toxicity is particularly noticeable in patients with fair skin,
and generalized exfoliation and peeling of hands and feet
can occur, often after patients are discharged from the
hospital. Lotions and emollients should be started at or
before the first sign of erythema.
Pruritus is not directly related to the degree of exfoliation.
A small study has shown that pruritus is not related to the
eosinophilia that sometimes develops with HD IL-2 admin-
istration. Pruritus may be cytokine mediated, as has been
shown in cutaneous T-cell leukemia in which T-cells infil-
trate the skin, or due to hyperbilirubinemia (49). Although
antihistamines are used for IL-2 induced pruritus, one
study has reported, and anecdotal reports have suggested,5 6
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boluses) during a cycle of HD IL-2. As the week progresses, weight
ally, vasopressor support is added before the final dose is administered.
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[49]. Itch nerve fibers are pain fibers and gabapentin is ef-
fective in peripheral neuropathy. If the pruritus is cytokine
mediated, and reflects irritation of peripheral nerves, then
gabapentin would be expected to be beneficial. In severe
cases opioids may be beneficial as the pain fiber-mediated
itch may respond to central acting agents. In patients
where the opiates administered for rigors are suspected as
the cause, naltrexone may be used to treat the itching.
Pruritus is not dose-dependent. It may not be resolved in
one week if the patient returns for the second cycle of IL-
2 treatment, and may be criteria for a delay. Skin man-
agement is an important part of discharge planning.
Electrolyte abnormalities
A variety of electrolyte abnormalities are noted, including
hypomagnesemia, hypocalcemia, hypokalemia, hypopho-
sphatemia and hyponatremia. These will progressively
worsen during the treatment and require careful correction
(Figure 3). Most centers correct the magnesium and potas-
sium, and monitor the others. Often the serum calcium is
normal after correcting for hypoalbuminemia.
Hematologic toxicity
Acute changes in the cellular elements of the blood are ex-
pected and may be dramatic (Figure 5). Thrombocytopenia
is a common toxicity of HD IL-2 therapy. However, it
rapidly reverses once IL-2 is discontinued and does not
require intervention in most cases. Patients with mM
who have received prior chemotherapy are at risk for
leukopenia during IL-2 therapy. It is not yet clear if mRCC
patients who have previously received anti-VEGF TKIs are
at risk of leukopenia.
One group studied the bone marrows of IL-2 patients
who developed thrombocytopenia and found normal1 2 3 4
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Figure 5 A logarithmic plot of blood lymphocyte, eosinophil, platelet an
IL-2 administration. Platelet and lymphocyte counts fall rapidly to very low lev
treatment, platelets and lymphocytes quickly return to normal and often rebounumbers and morphology of megakaryocytes. They attrib-
uted the thrombocytopenia to sequestration in the spleen
due to IL-2-induced splenomegaly (JPD, personal observa-
tion). Lymphocytes similarly disappear within hours after
the first dose, probably due to margination and diapedesis
into the tissues. Coagulation abnormalities have also
been reported. Fibrinogen and d-dimers were normal,
thus arguing against consumption or microthrombi and
suggesting impaired hepatic synthesis [50]. Coagulation
abnormalities and other hematologic toxicities rapidly
reverse with discontinuation of IL-2 and do not require
altered dosing of IL-2. Anemia can occur but rarely are
transfusions required. In fact, if patients become signifi-
cantly anemic during IL-2 administration, other causes,
such as hemorrhage, should be sought.
Hepatic enzyme and function abnormalities
The most frequent abnormalities noted are low albumin
(both from capillary leak and decreased synthesis), mild
coagulopathy, hyperbilirubinemia, and less commonly
hepatic enzyme elevations [51,52]. The bilirubin may rise to
approach 10 mg/dL and the albumin drop to 2 gr/dL or
less. These will reverse once IL-2 is discontinued. Some
sites discontinue acetaminophen if the bilirubin becomes
high, most do not. There does not appear to be a threshold
for bilirubin abnormalities for holding IL-2 or delaying
IL-2. Elevation of hepatic enzymes does cause some con-
cern when the value is 5–10 fold above normal and some
centers hold IL-2 for increases of this magnitude.
Criteria for holding or stopping HD IL-2
The main criteria used for holding and/or stopping IL-2
treatment are summarized in Table 3. The severity of
adverse events associated with bolus IL-2 peaks 4–6 hours
after a dose and most interventions will be employed at5 6
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d granulocyte absolute counts and hemoglobin during a cycle of HD
els. Eosinophils progressively rise during administration. After cessation of
nd to 2–5 times their baseline levels. Eosinophilia may persist for weeks.
Table 3 Criteria for holding and stopping IL2#
System Relative criteria Absolute criteria
Cardiovascular Sinus tachycardia 100–130 BPM* Sinus tachycardia > 130 BPM*
ECG indications of ischemia
Atrial fibrillation
Supraventricular tachycardia
Ventricular arrhythmias**
Elevated CKB-MB isoenzyme of troponin levels
Dermatologic Moist desquamation
Gastrointestinal Diarrhea, 1000 mL/shift Diarrhea 1000 mL/shift x 2
Vomiting not responsive to medication
Ileus/abdominal distention Severe abdominal distention affecting breathing
Bilirubin > 7 mg/dL Severe, unrelenting abdominal pain
Hemodynamic#* Maximum Phenylephrine 1–1.5 mcg/kg/min Maximum Phenylephrine 1.5-2.0 mcg/kg/min
Minimum Phenylephrine > 0.5 mcg/kg/min Minimum Phenylephrine > 0.8 mcg/kg/min
Hemorrhagic Sputum, emesis, or stool heme-positive Frank blood in sputum, emesis, or stool
Platelets 30,000-50,000/mm3 Platelets < 30,000 mm3
Infectious Strong clinical suspicion or documented
Musculoskeletal Weight gain > 15%
Extreme tightness Extreme paresthesias
Neurologic Vivid dreams Hallucinations
Mild anxiety Persistent crying
Mental status changes not reversible in 2 hours
Unable to subtract serial “7 s” or spell “WORLD” backward
Disorientation
Pulmonary Resting shortness of breath > 4 L O2 by nasal cannula or 40% by mask to
maintain≥ 95% O2 saturation
3–4 L O2 by nasal cannula for O2
saturation≥ 95%
Intubation
Rales 1/3 up chest Moist rales ½ up chest
Renal Urine output 80–160 mL/shift Urine < 80 mL/shift
Creatinine 2.5-2.9 mg/dL Creatinine≥ 3 mg/dL
HCO3 ≤ 18 meq/dL
Abbreviations: BPM, beats per minute; ECG, electrocardiogram.
*Persistent at the time of dosing after correcting hypotension, fever, and tachycardia and discontinuing dopamine.
**Including premature ventricular contractions, bigeminy, and tachycardia.
#In order to maintain acceptable BP and pulse criteria.
*Phenylephrine Max is during the interval, Min at the time of dosing.
#The above criteria should be assessed at the scheduled time of next dose after aggressive measures to correct toxicity have been undertaken.
If ≤ 3 relative criteria, delay dosing, continue corrective measures and administer another dose if recovered in < 24 hours.
If >3 relative criteria or an absolute criteria are observed stop IL-2 for the current cycle.
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receiving each dose to make sure that many of these
events are improving or have subsided at that time. Hold-
ing a dose of IL-2 is the preferred management of pro-
longed toxicity from a previous dose. There are no
individual dose reductions. If a toxicity occurs early in
the cycle and returns to near baseline, such as resolution
of elevated heart rate or low blood pressure, then treat-
ment can resume. However, toxicity is cumulative over
5 days, both in extent and duration. In addition, toxicitiesbecome increasingly refractory to treatment. Thus, later in
the week, more intensive or sustained toxicities become
reasons to stop that cycle of IL-2. Recommendations for
delaying, withholding or stopping IL-2 doses have evolved
from experience and are outlined below and in Table 3.
Cardiac
Holding
Sinus tachycardia is the norm after IL-2, but this should
return to a pre-defined baseline before administering
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100–120 beats per minute after correcting hypotension
in an afebrile patient, when a dose is due, that dose
should be delayed or skipped.
Stopping
Sustained rapid (>130-140/min) supraventricular tachy-
cardia or rapid atrial fibrillation will require intervention,
and stopping of IL-2, at least for the current cycle. If the
supraventricular arrhythmia can be converted to NSR
quickly or the heart rate and blood pressure managed
despite atrial fibrillation, then consideration could be
given to resuming IL-2 treatment. Once treated, IL-2
may be administered in a subsequent cycle. Ventricular
tachycardia or evidence of ischemic myocardial damage
are indications for permanently stopping IL-2 treatment.
A diagnosis of myocarditis should prompt discontinuation
of that cycle of IL-2, but if LVEF returns to baseline,
patients may cautiously proceed with additional cycles of
HD IL-2, usually without recurrence of this side effect.
Hypotension
Holding
IL-2 dosing should be delayed until hypotension recovers
from the previous dose and the vasopressor level (if
applicable) is at a baseline established for dosing. If
hypotension requires additional fluid boluses then an
assessment of respiratory function will help determine
when the next dose can be administered. If high doses of
phenylephrine continue to be required, some patients will
respond to replacing phenylephrine with norepinephrine at
low doses (prefer 2–4 mcg/kg/min but may titrate up to
10 mcg/kg/min for short periods of time). If high-doses of
vasopressors are needed, IL-2 should be discontinued.
Stopping
The degree and duration of significant hypotension pro-
gresses during the week, and thus may require more
fluid or higher doses of vasopressors to maintain adequate
blood pressure. When hypotension requires maximum
doses of vasopressors or a change to alternate vasopressors,
such norepinephrine, IL-2 should be stopped. IL-2 should
also be stopped if fluid overload precludes using fluids for
maintaining blood pressure, as pulmonary reserve may be
compromised.
Neurologic
Holding
Personality changes can be subtle, and it may be difficult
to distinguish when they are the result of IL-2 or from
other causes. However, if staff or family observe a change
in personality, exhibition of agitation or emotional lability,
IL-2 neurotoxicity must be considered. Improvement of
mild neuropsychiatric complications after drug therapy orafter delay of a dose of IL-2 is a sign to then continue
dosing.
Stopping
As a precipitous decline may occur with additional IL-2
doses, lack of improvement with specific therapy and
passage of time warrants stopping therapy. The progression
of personality changes or agitation to extreme emotional
lability, crying, aggressiveness, disorientation, or hallucina-
tions are absolute criteria for stopping IL-2. Such symp-
toms of neurotoxicity may require medication and
continued hospitalization until resolution. Rarely peripheral
compression neuropathy or vasospasm occurs, resulting in
finger pain or paresthesias poorly responsive to medication
which may also require stopping IL-2. This is more com-
mon during second or subsequent courses of therapy.
Pulmonary
Holding
Dyspnea and hypoxia reflect capillary leak and can lead to a
requirement for oxygen to maintain an oxygen saturation
of 95%. Oxygenation should be carefully monitored and
maintained. Patients may develop tachypnea and rales.
Tachypnea may also result from acidosis or fever which
should also be corrected. Delaying IL-2 administration will
allow diuresis spontaneously or with diuretics, and after
improvement, it may be possible to administer additional
IL-2. Patients may develop wheezing despite nebulizers and
this may reflect capillary leak or bronchospasm or both.
Careful diagnosis and aggressive correction of pulmonary
symptoms should occur quickly. The severity will influence
the decision to delay or discontinue IL-2 therapy.
Stopping
Patients with dyspnea or hypoxia requiring more than 4
liters of oxygen to maintain saturation of 95% or who are
clearly fluid overloaded are at risk for continuing IL-2.
Intubation should not be necessary with current guide-
lines, but is an absolute indication for stopping IL-2.
Oliguria/creatinine
Holding
Pre-established criteria at each center are used to determine
if urine output and serum creatinine are adequate to ad-
minister another dose. Some centers require urine output
of 30 ml/hour, others 80–160 ml/8 hour shift. Some centers
delay a dose of IL-2 when urine output has fallen, and
resume IL-2 when urine output is evident. Some centers
will only delay a dose if oliguria is accompanied by other
signs of significant toxicity, such as fluid overload that
does not allow further fluid replacement. Elevated serum
creatinine concentration alone is usually not a reason for
delaying a dose of IL-2, since it is primarily a reflection of
hypotension, capillary leak, and/or oliguria. However, many
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stop IL-2 treatment if the level rises above 3 to 5 mg/dL.
Dialysis is not necessary, as renal function returns upon
cessation of IL-2 administration.
Stopping
Each center will set its criteria for tolerability of oliguria
and/or serum creatinine level with which to hold or stop
IL-2. This is related to the degree of capillary leak, the
rate of rise of serum creatinine, the degree of oliguria,
and responsiveness to holding a dose of IL-2.
Diarrhea
Holding
If diarrhea becomes very frequent, such as 5–6 move-
ments/day of any volume, most centers would delay IL-2
therapy to allow some recovery. If diarrhea improves
with delaying doses, IL-2 may continue, but if as a con-
sequence of the diarrhea, the patient develops local pain
and irritation and fluid loss and electrolyte imbalance
are apparent holding another dose of IL-2 is prudent. If
there is concern about infection, treatment may have to
be discontinued. Electrolytes should be replaced as needed,
particularly bicarbonate, prior to resuming IL-2. Patients
who have had prior treatment with ipilimumab and develop
diarrhea while on high dose IL-2 should be evaluated for
inflammatory colitis.
Stopping
Rarely, continued large volume or frequent diarrhea despite
medical intervention requires stopping IL-2. Electrolyte loss
may not be compensated by replacement and due to the
depressed renal function overshoots of potassium are to be
avoided. If there is voluminous diarrhea, examination for
hemorrhagic diarrhea or C. difficile toxin should be ob-
tained. This is rare, but must be ruled out in this setting.
Metabolic acidosis
Holding
This can be a result of diarrheal losses of bicarbonate or
lactic acidosis due to tissue hypoperfusion. If replace-
ment controls the level of serum HCO3, then IL-2 can
be continued. Utilization of lactated Ringer’s instead of
half normal saline for maintainance fluid may prevent
low serum bicarbonate levels. The occurrence of a
serum HCO3 level of < 18 meq/dL is a worrisome sign
and must be promptly addressed. If it does not quickly
respond to bicarbonate replacement then an alternative
source of acid production, such as bowel ischemia,
should be considered and sought. For centers that use
Ringers Lactate as maintenance intravenous fluids, the
need for bicarbonate boluses has largely been eliminated,
as significant acidosis has not been observed.Stopping
Serum bicarbonate of < 18 meq/dL unresponsive to re-
placement therapy is reason for stopping IL-2.
Hematologic
Holding
Changes in blood counts are usually mild and not a reason
to hold IL-2. Platelet counts have been seen as low as in
the 20,000/mm3 range, but rapidly recover after stopping
IL-2. Some centers will transfuse, however, and stop on
the basis of thrombocytopenia, if more than 10 doses have
been administered.
Stopping
There is almost never a reduction in hemoglobin sufficient
to transfuse, so if that occurs, a search for additional
causes should be made. Examples may include bleeding
and in one case, pure red cell aplasia was noted in the
marrow immediately following IL-2 therapy (JPD, personal
communication).
Infection
Stopping
Any documented gastrointestinal or central line infection
or suspected sepsis is a criterion to stop IL2. Central
venous catheters should be promptly removed as line
infection can quickly proceed to septicemia particularly
if Staphylococcus aureus is the cause.
Cutaneous
Delay cycle
If severe cutaneous toxicity does not resolve mid-cycle, a
delay in the second week is sometimes necessary.
Stopping
Rarely pruritus or cutaneous toxicity can accelerate,
particularly during the second cycle of IL-2 treatment,
and the sensation may become intolerable, despite
treatment. This may be a criterion for stopping due to
patient discomfort.
Malaise/intolerance
Stopping
Patients may state that they cannot tolerate more treat-
ment and most IL-2 oncologists will stop IL-2 in the
face of extreme agitation or when patients do not wish
to continue.
Other
Clearly if there are issues that require transfer of a patient
to an ICU because of decompensation then IL-2 should
be discontinued at that time. This recommendation does
not apply to patients electively treated in an ICU setting
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ICU is necessary for the use of vasopressors.
Discharge management
Discharge planning should continue throughout the hospi-
talization, to familiarize the patient and home caregivers
with routines and expectations during the first few days
home. Once IL-2 is discontinued, patients recover very
quickly from its effects despite the cumulative toxicity
experienced during the cycle. Usually by 12 hours after
the last dose of IL-2 patients are anxious to leave the
hospital and return home. If they are still requiring
vasopressors, they must be weaned off and blood pressure
must be stable while they ambulate with assistance.
They should be prepared to sleep for several hours upon
returning home since they will still be experiencing signifi-
cant fatigue. Most sites advise patients not to drive or use
dangerous equipment for several days. Vivid dreams may
occur during the first several nights home which may be
frightening. Sleep medication may be needed short-term.
The serum creatinine usually levels off or begins to fall
by the time of discharge, but if it is still elevated, it usually
will normalize within the next several days. Some centers
prefer to recheck BUN and creatinine after discharge, but
experience has shown that this is unnecessary.
At discharge, patients will still have fluid overload, mostly
peripheral, and some centers provide a prescription for
diuretics to be used as needed, particularly if diuretics
were necessary in the hospital after IL-2 cessation.
Rarely, patients have fluid shifts from the periphery into
the pulmonary capillary bed, and develop late dyspnea
requiring diuresis. Patients receiving diuretics should
be instructed not to take them until they arrive at
home, in order to minimize risk of emergency stops on
the way home from the hospital.
Patients who have pre-existing hypertension will need
to resume their medications during the week between
cycles, usually starting 48 hours after discharge, and they
will have to stop these medications within 48 hours prior
to their next admission for IL-2. If patients are planning
further IL-2 treatment they should not re-start beta-
blockers.
For those patients who experience cutaneous manifes-
tations, the erythematous rash may evolve into extensive
peeling of the epidermis after hospital discharge, particu-
larly involving the palms and soles. Pruritus may worsen
after discharge, and creams should be used liberally as
well as increasing doses of gabapentin and potentially
opioids. Uncommonly, skin excoriation as a result of
pruritus may delay the second cycle of IL-2, if there are
open lesions and severe redness.
Hypothyroidism, sometimes preceded by an episode of
hyperthyroidism, can occur weeks or months after IL-2
therapy and thyroid function should be monitoredduring regular follow-up visits [53-55]. If a patient
returns for IL-2 therapy and is severely hypothyroid,
hormone replacement should be initiated. IL-2 should
be delayed until a euthyroid state is achieved on a stable
replacement dose.
Patients who are used to aerobic physical activity will
note that their stamina and lung capacity are less, immedi-
ately following IL-2. This will improve as they recondition.
These are delayed effects of capillary leak and cytokines on
the cardiopulmonary systems that spontaneously resolve.
The patient should be warned that iodinated contrast
media used in radiographic studies have caused skin and
systemic reactions in patients who have received prior
HD IL-2 [56]. These reactions may be intense and mimic
the side effects of IL-2, including oliguria and elevation
in creatinine levels. Hence, using iodinated contrast
agents immediately prior to retreatment with IL-2 should
be avoided.
Follow-up phone contact is important in the first one
to two weeks following IL-2 treatment, followed by regu-
lar follow-up visits with scans to assess disease status.
Follow-up scans are usually obtained 6–12 weeks after a
full course of IL-2 therapy is completed to assure that
there is no rapid growth of disease. Sometimes this scan
will in fact show an early response, or small growth with
subsequent response at the next scan. A second scan at
12–16 weeks will confirm whether benefit has occurred.
However, there have been patients who have demon-
strated continued response scan by scan over the course
of a year, and others who were stable for 6 months, and
then showed tumor regression. Other anecdotal reports
describe patients who have been stable and had residual,
previously biopsied disease resected, which was found to
be only scar tissue. Although the natural course of response
after IL-2 is not well defined, it may be important to allow
sufficient time for immunotherapy to work before changing
treatment approaches such as IL-2, as other forms of
immunotherapy has been associated with delayed kinet-
ics of tumor regression. Additionally for patients who
remain stable after IL-2 therapy, this appears to be of
clinical benefit and such patients may be monitored or
retreated [9,10,13].
Relapse of disease in patients that have previously
responded to IL-2 generally raises the question of retreat-
ment with IL-2. However, multiple factors will need to be
considered, such as the amount of prior IL-2 received, the
intensity of side effects experienced, and other treatment
options. In addition, it should be noted that retreatment
with IL-2 alone in this setting may be less effective [57].
Establishing HD IL2/immunotherapy centers
Clinical requirements
All personnel need to have specialized training in man-
aging HD IL-2 patients. Usual maneuvers to treat patients
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are managed very differently than HD IL-2 patients. Antici-
pation of the expected side effects, and rapid appropriate
correction are central to management of these patients.
Treating a minimum number of patients per year is import-
ant, as quality depends upon familiarity and repetition.
Nursing requirements The optimal scenario is that
there is sufficient nursing staff to have a reduced patient
ratio on all shifts such as 1 nurse to 2–3 patients. The
lower nurse to patient ratio of 1–2 may be necessary
during day 3, 4, or 5 of IL-2 treatment when the patient
is experiencing more varied and intense IL-2 side effects.
This may be less critical as the nursing staff becomes
more familiar with the management of HD IL-2 patients.
It is preferable to have cardiac monitoring, with BP, HR,
and oxygen saturation panels available for regular use.
Intensive in-service training should be provided for all
shifts and for new staff as needed. Patient comfort and
education are important nursing goals [58].
Physician commitment It is preferable that more than
one physician be trained and accept responsibility for
patient management. In some centers a group of only
medical oncologists or oncologic surgeons are responsible
and in others centers an oncologist will share management
with cardiology and pulmonary staff, either on the oncology
unit or in the ICU. Others utilize specially trained hospital-
ists or even oncology hospitalists for IL-2 management,
particularly at night. Nurse practitioners or physician assis-
tants have also maintained coverage in some centers with
backup support from a covering medical oncologist.
Immunotherapy coordinator This person(s) is usually a
nurse who is responsible for organizing the pre-screening
of patients for IL-2 eligibility, as well as obtaining insur-
ance approval. In most centers, this individual is also
involved in discharge management and follow-up for IL-2
patients and is fully aware of the special needs of their
management and follow-up.
Administrative issues
Prior to establishing the HD IL-2 treatment program, there
must be an evaluation of institutional policies regarding
cardiac monitoring and use of vasopressors on a regular
oncology unit, versus a requirement for ICU care. Manage-
ment of HD IL-2 is much more akin to a surgical proced-
ure where the patient is admitted with an expectation of a
standard length of admission and utilization of a predict-
able amount of hospital resource with a discharge home of
a convalescing patient. If IL-2 is to be given on a regular
unit, an assessment of what type of nursing training will be
required for cardiac monitoring, frequent vital signs, and
vasopressor management will need to be made. Attentionto integrating clinical assessment and pharmacy prepar-
ation of the drug is also important to avoid wasting drug
or inadvertent administration to a patient experiencing a
significant toxicity. Based on these issues, the following
two key questions will need to be addressed: Where in
the hospital will HD IL2 be administered? Who will be
responsible for patient management?
Regardless of the setting, low nurse/patient ratios, experi-
ence in managing complex acutely ill patients and consist-
ent practice in these settings is critical. HD IL-2 specific
training for all personnel is essential to success. Hospital
policies and availability of resources often determines where
HD IL-2 is administered.
ICU setting
Some centers only use vasopressors in an ICU. Nursing
staff levels may also be an issue for non-ICU management
in some institutions. ICU nurses must be specifically
trained in management of IL-2 patients, as HD IL-2 man-
agement decisions are often counter intuitive to standard
ICU practice. Staff should comply with chemotherapy
certification if hospital policy dictates, but it is not
necessary. In the ICU, there must be clear delineation of
which physician team will have primary responsibility for
the patients. Ideally, it should be the HD IL-2 team, rather
than the ICU physicians.
Hematopoietic Stem Cell Transplant/HD IL-2 Unit: A
high intensity oncology unit is available at some centers.
IL-2 treatment and stem cell transplant both require
intensive nursing, monitoring and management. This is
a natural setting for HD IL-2.
Inpatient oncology unit
Experienced high volume centers often administer all
HD IL-2 on a standard oncology unit equipped for cardiac
monitoring. Alternatively, sites may start treatment on an
oncology unit and transfer to ICU when it is necessary to
monitor and administer vasopressors. If transfer to an
ICU does occur, the same medical team should have
primary responsibility for the care of the patient.
All these facets of care should be clearly defined and
agreed upon by all parties before training, instruction,
and treatment begins.
Financial/Billing issues
There must be an education of medical records and billing
staff to allow optimal documentation for coding and bill-
ing for the level of intensity of HD IL-2 administration.
They must be cognizant of the dedicated DRG and CPT
codes for IL-2 administration. A training session can be
provided for instruction in recognizing the specific terms
and converting to specific coding for IL-2.
Medical and nursing personnel who are documenting
care and management of these patients need to be
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the severity of illness during IL-2 administration.
Some institutions will require a cost analysis prior to
initiating and supporting an IL-2 program.
Conclusions
High dose interleukin-2 remains an important component
of the therapeutic armamentarium for patients with meta-
static renal cell cancer and metastatic melanoma. A subset
of these patients continue to achieve a consistent durable
complete response that can last for decades. The authors
agree that peri-treatment mortality can be reduced to less
than 1% when guidelines are diligently followed. High
priority research includes an exploration of combination
therapy wherein IL-2 is used with other immunotherapy
agents, stereotactic radiation, or new targeted therapeutics
being developed for these diseases [44,59]. Another high
priority is the identification and validation of predictive
biomarkers to better select potential responders prior to
treatment. The education of more physicians in how to
administer HD IL-2 and manage patients on treatment
can increase the number of patients who might benefit
from the therapy. This Best Practices manuscript has been
developed to further enhance guidance for administration
of HD IL-2 by surveying the experience of more than 20
experts with years of experience in its utilization.
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